Chiron's Triacelluvax DTaP Approval In Europe Reflects Italian Trial
Executive Summary
The approval of Chiron's Triacelluvax diphtheria, tetanus and pertussis vaccine in Europe reflects the acceptance of protective efficacy data from a 15,601-patient Italian trial, the European Public Assessment Report indicates.